HighTower Advisors LLC Raises Holdings in Agenus Inc. (NASDAQ:AGEN)

HighTower Advisors LLC increased its position in Agenus Inc. (NASDAQ:AGEN) by 46.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 23,851 shares of the biotechnology company’s stock after purchasing an additional 7,530 shares during the period. HighTower Advisors LLC’s holdings in Agenus were worth $122,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AGEN. Ovata Capital Management Ltd purchased a new stake in Agenus in the second quarter valued at approximately $670,000. Federated Hermes Inc. acquired a new position in shares of Agenus in the 2nd quarter valued at $1,921,000. Blair William & Co. IL purchased a new stake in Agenus in the 2nd quarter valued at $441,000. Point72 DIFC Ltd purchased a new stake in Agenus in the 2nd quarter valued at $51,000. Finally, Squarepoint Ops LLC acquired a new stake in Agenus during the 2nd quarter worth $614,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $2.81 on Friday. The stock has a fifty day moving average price of $3.49 and a 200 day moving average price of $6.66. Agenus Inc. has a 1-year low of $2.50 and a 1-year high of $19.69. The company has a market cap of $65.92 million, a PE ratio of -0.25 and a beta of 1.24.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.